Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies. Chlon, TM; Patnaik, MM. American Journal of Hematology. 2023; 98:1673-1676.

Abstract A46: Heterozygous mutations in DDX41 cause erythroid progenitor cell defects and cooperate with p53 mutations to cause hematologic malignancy. Chlon, TM; Stepanchick, E; Sulentic, A; Wilson, A; Starczynowski, DT. 2023; 4:a46.

Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms. Badar, T; Chlon, T. Current Hematologic Malignancy Reports. 2022; 17:113-120.

The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Niederkorn, M; Ishikawa, C; M. Hueneman, K; Bartram, J; Stepanchick, E; R. Bennett, J; E. Culver-Cochran, A; Bolanos, LC; Uible, E; Choi, K; Wunderlich, M; Perentesis, JP; M. Chlon, T; Filippi, MD; Starczynowski, DT. Leukemia. 2022; 36:438-451.

Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Chlon, TM; Stepanchick, E; Hershberger, CE; Daniels, NJ; Hueneman, KM; Kuenzi Davis, A; Choi, K; Zheng, Y; Gurnari, C; Haferlach, T; Padgett, RA; Maciejewski, JP; Starczynowski, DT. Cell Stem Cell. 2021; 28:1966-1981.e6.

Inherited DNA Repair Defects Disrupt the Structure and Function of Human Skin. Ruiz-Torres, S; Brusadelli, MG; Witte, DP; Wikenheiser-Brokamp, KA; Sauter, S; Nelson, AS; Sertorio, M; Chlon, TM; Lane, A; Mehta, PA; Komurov, K; Kovacic, MB; Davies, SM; Wells, SI. Cell Stem Cell. 2021; 28:424-435.e6.